Antonia Högnäsbacka

Publications
Public outreach and news

Articles

Article: JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS. 2024;67(6):245-249
Validation of a good manufacturing practice procedure for the production of [¹¹C]AZD4747, a CNS penetrant KRAS^G12c inhibitor
Gonzalez MAC; Hognasbacka AA; Halldin C; Schou M
Article: EJNMMI RESEARCH. 2024;14(1):19
Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor.
Högnäsbacka AA; Poot AJ; Plisson C; Bergare J; Bonsall DR; McCluskey SP; Wells LA; Kooijman E; Schuit RC; Verlaan M; Beaino W; van Dongen GAMS; Vugts DJ; Elmore CS; Passchier J; Windhorst AD
Article: JOURNAL OF MEDICINAL CHEMISTRY. 2023;66(17):12130-12140
Synthesis and Preclinical Evaluation of [Methylpiperazine-11C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase.
Högnäsbacka AA; Poot AJ; Kooijman E; Schuit RC; Schreurs M; Verlaan M; Beaino W; van Dongen GAMS; Vugts DJ; Windhorst AD
Article: NUCLEAR MEDICINE AND BIOLOGY. 2023;120-121:108349
Synthesis and preclinical evaluation of two osimertinib isotopologues labeled with carbon-11 as PET tracers targeting the tyrosine kinase domain of the epidermal growth factor receptor.
Högnäsbacka A; Poot AJ; Kooijman E; Schuit RC; Schreurs M; Verlaan M; van den Hoek J; Heideman DAM; Beaino W; van Dongen GAMS; Vugts DJ; Windhorst AD
Article: JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS. 2022;65(10-11):288-291
Simplified and accessible [¹⁸F]F-AraG synthesis procedure for preclinical PET
Hognasbacka AA; Gonzalez MAC; Halldin C; Schou M

All other publications

Review: PHARMACEUTICALS. 2022;15(4):450
The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor.
Högnäsbacka A; Poot AJ; Vugts DJ; van Dongen GAMS; Windhorst AD

Articles

All other publications

News from KI

Events from KI